[测定卵巢癌患者血清中肿瘤标志物癌胚抗原（CEA）、糖类抗原125（CA125）和糖类抗原72-4（CA72-4）的意义]

[Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].

作者信息

Kokocińska D, Worwag J, Tomala J, Dzieciuchowicz L, Nowak S, Kuśmierski S

机构信息

Katedry i Kliniki Chirurgii Ogólnej Slaskiej Akademii Medycznej w Katowicach.

出版信息

Ginekol Pol. 1994 Sep;65(9):495-501.

PMID:7721162

Abstract

Serum levels of 3 markers: CEA, CA125 and CA72-4 have been determined in 58 patients aged from 15-60 years with histologically diagnosed ovarian cancer. Serum CEA was determined by radioimmunoassay using kits POLATOM (Poland), CA72-4 was determined using kits CIS BIOINTERNATIONAL (France) and CA125 was determined by enzyme immunoassay using kits Hoffmann-la-Roche (Wien-Austria). We have observed the growth of sensitivity and specificity of serum levels: CA125 and CA72-4 if we have referred to the simultaneous elevation of CA125 and CA72-4 markers. We have observed that CA125 and CA72-4 elevated levels were proceeded clinical recurrent of the disease from 2 to 6 months.

摘要

对58例年龄在15至60岁之间、经组织学诊断为卵巢癌的患者测定了3种标志物（癌胚抗原（CEA）、糖类抗原125（CA125）和糖类抗原72-4（CA72-4））的血清水平。血清CEA采用波兰POLATOM试剂盒通过放射免疫测定法测定，CA72-4采用法国CIS BIOINTERNATIONAL试剂盒测定，CA125采用奥地利维也纳霍夫曼-罗氏试剂盒通过酶免疫测定法测定。如果参考CA125和CA72-4标志物同时升高的情况，我们观察到血清水平（CA125和CA72-4）的敏感性和特异性有所提高。我们观察到，CA125和CA72-4水平升高发生在疾病临床复发前2至6个月。